195 related articles for article (PubMed ID: 37380347)
1. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors.
Karagkounis D
Drug Ther Bull; 2023 Jul; 61(7):103-107. PubMed ID: 37380347
[TBL] [Abstract][Full Text] [Related]
2. The role of sodium-glucose co-transporter (SGLT)-2 inhibitors in heart failure management and implications for the kidneys.
Lioudaki E; Joslin JR; Trachanatzi E; Androulakis E
Rev Cardiovasc Med; 2022 Mar; 23(3):82. PubMed ID: 35345249
[TBL] [Abstract][Full Text] [Related]
3. Focused Updates: SGLT2 Inhibitors in Patients With Heart Failure and/or Chronic Kidney Disease.
Cheng JWM; Colucci V; Kalus JS; Spinler SA
Ann Pharmacother; 2021 Feb; 55(2):252-260. PubMed ID: 32536199
[TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose co-transporter 2 inhibitors in patients with chronic kidney disease.
Solomon J; Festa MC; Chatzizisis YS; Samanta R; Suri RS; Mavrakanas TA
Pharmacol Ther; 2023 Feb; 242():108330. PubMed ID: 36513134
[TBL] [Abstract][Full Text] [Related]
5. Cardio-renal benefits of sodium-glucose co-transporter 2 inhibitors in heart failure with reduced ejection fraction: mechanisms and clinical evidence.
Aguilar-Gallardo JS; Correa A; Contreras JP
Eur Heart J Cardiovasc Pharmacother; 2022 May; 8(3):311-321. PubMed ID: 34264341
[TBL] [Abstract][Full Text] [Related]
6. Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes.
Gronda EG; Vanoli E; Iacoviello M; Urbinati S; Caldarola P; Colivicchi F; Gabrielli D
Heart Fail Rev; 2023 May; 28(3):723-732. PubMed ID: 35098383
[TBL] [Abstract][Full Text] [Related]
7. Expanding the Role of SGLT2 Inhibitors Beyond Diabetes: A Case-Based Approach.
Wong E; Nguyen TV
Sr Care Pharm; 2023 Jun; 38(6):233-238. PubMed ID: 37231576
[TBL] [Abstract][Full Text] [Related]
8. Effects of sodium-glucose co-transporter-2 inhibitors on kidney, cardiovascular, and safety outcomes in patients with advanced chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
Cao H; Rao X; Jia J; Yan T; Li D
Acta Diabetol; 2023 Mar; 60(3):325-335. PubMed ID: 36316605
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.
Tsai WC; Hsu SP; Chiu YL; Yang JY; Pai MF; Ko MJ; Tu YK; Hung KY; Chien KL; Peng YS; Wu HY
BMJ Open; 2022 Oct; 12(10):e060655. PubMed ID: 36241355
[TBL] [Abstract][Full Text] [Related]
10. SGLT2 Inhibitors in Patients With Heart Failure and Chronic Kidney Disease: Jigsaw Falling Into Place.
Kristensen SL; Jensen J; Schou M
J Am Coll Cardiol; 2023 May; 81(19):1915-1917. PubMed ID: 37164524
[No Abstract] [Full Text] [Related]
11. Factors affecting prescription of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes mellitus with established cardiovascular disease/ chronic kidney disease in Hong Kong: a qualitative study.
Ng NM; Ng YS; Chu TK; Lau P
BMC Prim Care; 2022 Dec; 23(1):317. PubMed ID: 36476327
[TBL] [Abstract][Full Text] [Related]
12. SGLT2 inhibitors in people with and without T2DM.
Khunti K
Nat Rev Endocrinol; 2021 Feb; 17(2):75-76. PubMed ID: 33293703
[No Abstract] [Full Text] [Related]
13. Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease.
Chan JSK; Perone F; Bayatpoor Y; Tse G; Harky A
Expert Opin Pharmacother; 2023 Jun; 24(8):935-945. PubMed ID: 37070470
[TBL] [Abstract][Full Text] [Related]
14. Do four SGLT2 inhibitors lead to different cardiorenal benefits in type 2 diabetes, in chronic heart failure, and in chronic kidney disease?
Qiu M; Ding LL; Zhan ZL; Zhou HR
Eur J Intern Med; 2021 May; 87():98-99. PubMed ID: 33485738
[No Abstract] [Full Text] [Related]
15. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
[TBL] [Abstract][Full Text] [Related]
16. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
O'Meara E; Verma S
Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
[TBL] [Abstract][Full Text] [Related]
17. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
[TBL] [Abstract][Full Text] [Related]
18. Use of sodium-glucose co-transporter 2 inhibitors in solid organ transplant recipients with pre-existing type 2 or post-transplantation diabetes mellitus: A systematic review.
Lin Y; Mok M; Harrison J; Battistella M; Farrell A; Leung M; Cheung C
Transplant Rev (Orlando); 2023 Jan; 37(1):100729. PubMed ID: 36427372
[TBL] [Abstract][Full Text] [Related]
19. Can chronic kidney disease lead to chronic heart failure, and does worsening chronic heart failure lead to chronic kidney disease progression.
Leon SJ; Tangri N
Curr Opin Nephrol Hypertens; 2022 Mar; 31(2):205-211. PubMed ID: 34954720
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose cotransporter 2 inhibitors in heart failure with chronic kidney disease.
Kato S; Horita N; Utsunomiya D
ESC Heart Fail; 2022 Oct; 9(5):3661-3662. PubMed ID: 35876022
[No Abstract] [Full Text] [Related]
[Next] [New Search]
